Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Monday, 26'th Aug 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
04:05pm, Wednesday, 21'st Aug 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)
05:31pm, Friday, 09'th Aug 2024
Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, w
Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript
05:21pm, Friday, 09'th Aug 2024
Arcus Biosciences, Inc. (NYSE:RCUS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President-Investor Relations and Strategy Terry Rosen – Chief
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
07:15pm, Thursday, 08'th Aug 2024
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.04 per share a year ago.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:05am, Thursday, 01'st Aug 2024
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 25'th Jun 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 11'th Jun 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
11:56am, Friday, 07'th Jun 2024
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Thursday, 06'th Jun 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
SECAUCUS, N.J.--(BUSINESS WIRE)-- #AI--ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the N
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 stud
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Friday, 24'th May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
